A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy
about
Immunovirological parameters and cytokines in HIV infectionInfluence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virusInterferon-alpha, immune activation and immune dysfunction in treated HIV infectionInnate immune responses and rapid control of inflammation in African green monkeys treated or not with interferon-alpha during primary SIVagm infectionMechanistic insights on immunosenescence and chronic immune activation in HIV-tuberculosis co-infectionCognitive Consequences of Aging with HIV: Implications for Neuroplasticity and Rehabilitation.Contribution of intestinal barrier damage, microbial translocation and HIV-1 infection status to an inflammaging signatureRuxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro.Plasma IP-10 Concentrations Correlate Positively with Viraemia and Inversely with CD4 Counts in Untreated HIV InfectionImmunological and virological characterization of HIV-1 viremia controllers in the North Region of Brazil.HIV persistence: chemokines and their signalling pathways.Anti-retroviral therapy decreases but does not normalize indoleamine 2,3-dioxygenase activity in HIV-infected patients.Persistence of Activated and Adaptive-Like NK Cells in HIV+ Individuals despite 2 Years of Suppressive Combination Antiretroviral Therapy.Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism.Aging of the human innate immune system in HIV infection.Cocaine alters cytokine profiles in HIV-1-infected African American individuals in the DrexelMed HIV/AIDS genetic analysis cohortAcute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection.Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women.Elevated plasma soluble CD14 and skewed CD16+ monocyte distribution persist despite normalisation of soluble CD163 and CXCL10 by effective HIV therapy: a changing paradigm for routine HIV laboratory monitoring?HIV-1 infection induces strong production of IP-10 through TLR7/9-dependent pathwaysThe effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation.Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.Silymarin suppresses basal and stimulus-induced activation, exhaustion, differentiation, and inflammatory markers in primary human immune cellsProgramming of neurotoxic cofactor CXCL-10 in HIV-1-associated dementia: abrogation of CXCL-10-induced neuro-glial toxicity in vitro by PKC activator.Systemic Immune Activation Profiles of HIV-1 Subtype C-Infected Children and Their MothersLongitudinal Assessment of Systemic and Genital Tract Inflammatory Markers and Endogenous Genital Tract E. coli Inhibitory Activity in HIV-Infected and Uninfected Women.Study design issues in evaluating immune biomarkers.Dynamics of cytokine/chemokine responses in intestinal CD4+ and CD8+ T Cells during Acute Simian Immunodeficiency Virus InfectionSalivary inflammatory mediator profiling and correlation to clinical disease markers in asthma.Applications and limitations of inflammatory biomarkers for studies on neurocognitive impairment in HIV infection.Circulating biomarkers of immune activation distinguish viral suppression from nonsuppression in HAART-treated patients with advanced HIV-1 subtype C infection.Cognitive consequences of a sustained monocyte type 1 IFN response in HIV-1 infectionConnecting the dots: could microbial translocation explain commonly reported symptoms in HIV disease?Time-dependent ROC analysis for censored biomarker data due to limit of detection.Neurocognitive dysfunction in HIV-infected youth: investigating the relationship with immune activation.Evidence for a different susceptibility of primate lentiviruses to type I interferons.Impact of HIV on the severity of influenza.Brain Macrophages in Simian Immunodeficiency Virus-Infected, Antiretroviral-Suppressed Macaques: a Functional Latent Reservoir.The Aging Population with HIV Infection.Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy.
P2860
Q26829264-46956750-1DBC-4AAD-BE33-48E56BA9C11BQ26851535-079AE3C1-374B-4685-8954-DBF8989809F6Q26861003-57D9A6C0-AB88-4A8F-857F-33E1450960F1Q27324621-B3069626-7253-43B5-997B-738A065B58FCQ28081838-598B6A21-D34D-4717-A606-8158EE135059Q33579178-24382683-6399-42FB-802B-1B7E7AE7857AQ33599291-7202BA59-3A7E-408A-B910-EE17D136372FQ33622771-C90EB663-92C3-423D-8E41-4E4EED94157AQ33668482-0BD7C1A2-7746-464E-806B-E765364A2100Q33755753-E9D7EDD6-2155-4616-AD20-429CAA94339DQ33774665-50639245-CFEF-43BB-8C2E-BA5E67FCFFC8Q33830637-D7696BF1-AB83-43CA-B16B-1CDE1E3D1502Q33854427-12750079-1A48-4736-BFB2-4B2A906C828DQ33889154-9BE651B6-E5AD-498C-A70C-122C59EB76CFQ34094201-F388FD40-D844-456E-AC33-BD998F77898CQ34097854-A4475F90-9120-4662-BECA-BC38D4ED017AQ34441167-1212DDFF-B386-4FAC-A814-81B1A829A631Q34568436-820B0CDB-EBFE-460A-BE56-116B801C8816Q34784783-E68F1B8F-143B-44E4-9F04-FA2B4F0EA7B5Q34889163-D3CB9926-C86D-42EF-806B-C72236F6EA93Q35030011-85CFC577-ACF4-40B5-8A48-F5F27D75D023Q35109483-181F2CF1-6A7C-4E26-BE4A-56F06D568C95Q36269639-24883C51-F44B-4525-BA92-B79D844F22DAQ36498596-E2B955F4-7BA0-4AD3-A432-81C49D82DC2EQ36670411-A754287E-F5CC-4142-9AB2-AA5E902F91B3Q36927695-9EF8D102-2B66-4D07-B828-E2C224019B42Q37184783-602DCE51-F1FA-4E24-B1E1-0DE6C7DAE429Q37252772-592331A8-AD1D-4ABE-B790-1F1B8DAF7877Q37444881-3EB30748-9A7F-4F32-BFD3-0FC69E2D02DAQ37467991-F11F37CB-5D0A-4C23-9CFB-D93DC27EB800Q37720298-7088716A-11DB-4B54-AECF-437A6ABCBCB7Q38214994-9A202E60-0D81-4781-9035-FAE8FF287435Q38259086-4467B1F6-57E3-4CC6-9743-B766313968CFQ38598117-6958370F-0D5A-4C71-B534-9840F2260CBCQ38887687-5F32A5C3-0FD4-4A4A-B2E2-A8C6280979A9Q39223017-3F9A9D50-5758-43D2-A474-F03831B491EEQ39966481-033853AC-6F2E-4DDA-9DED-344B80054554Q40082046-7C8D6181-F413-4F50-9150-D757BC7A7DB2Q40101352-FF0DFD5C-D9C7-4C22-85F5-C52E6461D94EQ41257300-AA7F7086-35CB-40A1-82C0-35E553E4C652
P2860
A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
A plasma biomarker signature o ...... ents on antiretroviral therapy
@ast
A plasma biomarker signature o ...... ents on antiretroviral therapy
@en
A plasma biomarker signature o ...... ents on antiretroviral therapy
@nl
type
label
A plasma biomarker signature o ...... ents on antiretroviral therapy
@ast
A plasma biomarker signature o ...... ents on antiretroviral therapy
@en
A plasma biomarker signature o ...... ents on antiretroviral therapy
@nl
prefLabel
A plasma biomarker signature o ...... ents on antiretroviral therapy
@ast
A plasma biomarker signature o ...... ents on antiretroviral therapy
@en
A plasma biomarker signature o ...... ents on antiretroviral therapy
@nl
P2093
P2860
P921
P1433
P1476
A plasma biomarker signature o ...... ents on antiretroviral therapy
@en
P2093
Anupa Kamat
Dana Gabuzda
Edana Cassol
Petronela Ancuta
Vikas Misra
Zhenyu Yan
P2860
P304
P356
10.1371/JOURNAL.PONE.0030881
P407
P577
2012-01-01T00:00:00Z